Prof. Yimin Zhu: Professor at SINANO, CAS, China
Zhu Yimin is a highly regarded researcher and Director at the Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences. She has made significant contributions to the fields of nanomedicine, tumor immunotherapy, and advanced nano-delivery systems. Her innovative research has led to breakthroughs in the design of peptide-based therapies for cancer and the development of intelligent biomaterials for targeted drug delivery. She has authored over 40 high-impact publications and holds more than 10 patents, reflecting her commitment to advancing biomedical science.
Online Profiles
Research Metrics:
- Citations: 1,533 citations across 1,493 documents
- Publications: 40 documents
- h-index: 19
Prof. Yimin Zhu is a leading researcher specializing in biomedicine, nanotechnology, and tumor immunotherapy. Her work focuses on developing advanced nano-delivery systems, functional peptide screening platforms, and innovative biotechnology applications. Prof. Zhu has contributed extensively to the scientific community through her research, publications, and patents.
Education
Dr. Zhu earned her master’s degree in clinical medicine through a rigorous seven-year program at Tianjin Medical University, graduating in 1996. She then pursued a PhD in Biochemistry at the National University of Singapore, where she conducted groundbreaking research on cellular signaling and nano-bio interactions. She submitted her doctoral thesis in 2004 and officially received her degree in 2005, marking the beginning of her journey in nanotechnology and biomedical sciences.
Research Focus
Dr. Zhu’s research focuses on integrating nanotechnology with biomedicine to address critical healthcare challenges. Her work includes developing functional peptide screening platforms, creating intelligent composite nano-delivery systems, and advancing tumor immunotherapy. By leveraging the unique properties of nanomaterials, she has contributed to breakthroughs in cancer treatment and immunotherapy, including the design of peptide-based CAR T cells and PD-1 blockade therapies.
Experience
With a career spanning over two decades, Dr. Zhu has balanced clinical, academic, and industrial research roles. She began as a neurologist in Tianjin, transitioned to biochemistry research during her PhD studies in Singapore, and conducted postdoctoral research in chemical engineering at the University of California, Santa Barbara. Since 2008, she has been leading key projects at the Suzhou Institute of Nano-Tech and Nano-Bionics, where she also heads the Ethics Committee and the Animal Management Committee.
Research Timeline
- 1996–2004: Transitioned from clinical medicine to biochemical research during her master’s and PhD studies.
- 2005–2008: Conducted postdoctoral research in chemical engineering at the University of California, Santa Barbara, focusing on nano-biomaterials.
- 2008–Present: Leads groundbreaking research on nanotechnology and biomedicine at the Suzhou Institute of Nano-Tech and Nano-Bionics, heading multiple national and international collaborative projects.
Awards & Honors
Dr. Zhu has received numerous accolades for her innovative contributions, including funding from the National Natural Science Foundation and the Jiangsu Provincial Social Development Project. Her work has been recognized with awards for excellence in research and innovation in nanomedicine. She is also a recipient of institutional honors for her leadership in advancing biomedical technologies.
Top-Noted Publications
Dr. Zhu has authored several influential papers, including:
The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy
Authors: Liu, C., Wang, Q., Li, L., … Zhang, Y., Zhu, Y.
Journal: International Journal of Pharmaceutics, 2024, Vol. 663, Article 124558
Citations: 1
Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress
Authors: Qin, Y., Meng, X., Li, L., … Huang, Y., Zhu, Y.
Journal: European Journal of Pharmacology, 2023, Vol. 960, Article 176144
Citations: 0
Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment
Authors: Zhou, Y., Li, L., Zhou, D., … Zhu, Y., Cui, Y.
Journal: International Immunopharmacology, 2023, Vol. 123, Article 110760
Citations: 1
Identification of cancer protein biomarker based on cell-specific peptide and its potential role in predicting tumor metastasis
Authors: Li, L., Liu, C., Qin, Y., … Wang, Q., Zhu, Y.
Journal: Journal of Proteomics, 2023, Vol. 275, Article 104826
Citations: 3
Extracellular Vesicle‐Based Nanodrug Delivery (Book Chapter)
Authors: Yin, W., Pham, C.V., Patel, S., … Zhu, Y., Duan, W.
Book: Supramolecular Nanotechnology: Advanced Design of Self-Assembled Functional Materials, Volumes 1-3, 2023, Vol. 2, pp. 667–688
Citations: 1
Prof. Zhu’s work spans key advancements in cancer immunotherapy, tumor biology, and nanotechnology-based drug delivery, making significant contributions to biopharmaceutical research and applications.